Pablo E Pergola

Summary

Publications

  1. ncbi A randomized controlled study of weekly and biweekly dosing of epoetin alfa in CKD Patients with anemia
    Pablo E Pergola
    Renal Associates, PA, 215 East Quincy Street, Suite 610, San Antonio, TX 78215
    Clin J Am Soc Nephrol 4:1731-40. 2009
  2. ncbi A randomized controlled study comparing once-weekly to every-2-week and every-4-week dosing of epoetin alfa in CKD patients with anemia
    Pablo E Pergola
    Renal Associates PA, 215 East Quincy Street, Suite 610, San Antonio, TX 78215, USA
    Clin J Am Soc Nephrol 5:598-606. 2010
  3. ncbi Bardoxolone methyl and kidney function in CKD with type 2 diabetes
    Pablo E Pergola
    Renal Associates, San Antonio, TX 78215, USA
    N Engl J Med 365:327-36. 2011
  4. ncbi Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD
    Pablo E Pergola
    Renal Associates, PA, San Antonio, Tex, USA
    Am J Nephrol 33:469-76. 2011
  5. ncbi Body temperature regulation during hemodialysis in long-term patients: is it time to change dialysate temperature prescription?
    Pablo E Pergola
    Division of Nephrology, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229 3900, USA
    Am J Kidney Dis 44:155-65. 2004

Detail Information

Publications5

  1. ncbi A randomized controlled study of weekly and biweekly dosing of epoetin alfa in CKD Patients with anemia
    Pablo E Pergola
    Renal Associates, PA, 215 East Quincy Street, Suite 610, San Antonio, TX 78215
    Clin J Am Soc Nephrol 4:1731-40. 2009
    ..The primary objective was to show that treatment with epoetin alfa at QW and Q2W intervals was not inferior to TIW dosing...
  2. ncbi A randomized controlled study comparing once-weekly to every-2-week and every-4-week dosing of epoetin alfa in CKD patients with anemia
    Pablo E Pergola
    Renal Associates PA, 215 East Quincy Street, Suite 610, San Antonio, TX 78215, USA
    Clin J Am Soc Nephrol 5:598-606. 2010
    ..This study aimed to demonstrate that EPO dosed every 2 weeks (Q2W) and every 4 weeks (Q4W) was noninferior to once-weekly (QW) dosing...
  3. ncbi Bardoxolone methyl and kidney function in CKD with type 2 diabetes
    Pablo E Pergola
    Renal Associates, San Antonio, TX 78215, USA
    N Engl J Med 365:327-36. 2011
    ..Bardoxolone methyl, an oral antioxidant inflammation modulator, has shown efficacy in patients with CKD and type 2 diabetes in short-term studies, but longer-term effects and dose response have not been determined...
  4. ncbi Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD
    Pablo E Pergola
    Renal Associates, PA, San Antonio, Tex, USA
    Am J Nephrol 33:469-76. 2011
    ..Bardoxolone methyl, a novel synthetic triterpenoid, induces Nrf2, a transcription factor known to play a key role in decreasing oxidative stress and the production of pro-inflammatory molecules...
  5. ncbi Body temperature regulation during hemodialysis in long-term patients: is it time to change dialysate temperature prescription?
    Pablo E Pergola
    Division of Nephrology, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229 3900, USA
    Am J Kidney Dis 44:155-65. 2004
    ..0 degrees C in all patients unless contraindicated...